SCHEDULE: Suvretta Capital Discloses 9.9% Stake in ArriVent
Beneficial Ownership Disclosure
Suvretta Capital Management, LLC and its affiliates have disclosed a 9.9% beneficial ownership stake in ArriVent BioPharma, Inc. common stock.
Summary
- Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in ArriVent BioPharma, Inc.
- Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 3,412,788 shares of ArriVent BioPharma, Inc. common stock, representing 9.9% of the class.
- Averill Master Fund, Ltd. beneficially owns 2,969,098 shares, representing 8.7% of the class.
- All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC.
- Averill Master Fund, Ltd. is the only advisory client known to beneficially own more than 5% of the Common Stock.
- Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing indicates significant institutional investment in ArriVent BioPharma, Inc., a company operating in the biotechnology or pharmaceutical sector. Such disclosures are common as investment firms adjust their portfolios and cross certain ownership thresholds, reflecting their confidence or strategic positioning within specific industry players.
Related Party Transactions
- Aaron Cowen is the control person for Suvretta Capital Management, LLC, which manages funds including Averill Master Fund, Ltd., all of whom are reporting beneficial ownership.
Stakeholder Impact
- Shareholders may view the significant stake held by institutional investors like Suvretta Capital Management as a vote of confidence, potentially influencing market perception and trading activity.
- The disclosure provides transparency to the market regarding major ownership positions, which is crucial for all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/13/2025 | Signature date of the Schedule 13G Amendment No. 1 |
Keywords
ArriVent BioPharma, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Beneficial Ownership, Schedule 13G, Common Stock, Biopharma Investment, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.